Inventor · disambiguated record
C. Frank Bennett
Also filed as: BENNETT C · BENNETT C F · BENNETT C FRANK · BENNETT FRANK C
202 granted patents·194 pending applications·9,017 citations·filing 1993–2024
99Inventor score
Files withISIS PHARMACEUTICALS INC202IONIS PHARMACEUTICALS INC45BENNETT C FRANK29REGULUS THERAPEUTICS INC17BENNETT C F15
Top patents by PatentIndex Score
396 records- 0199US8110558B2Oligomeric compounds and compositions for use in modulation of small non-coding RNASBENNETT C FRANK·Filed 2008·Granted Feb 7, 2012·61 cites·25 claims
- 0299US8106025B2Method for inhibiting the activity of mir-155BENNETT C FRANK·Filed 2008·Granted Jan 31, 2012·45 cites·22 claims
- 0399US7745609B2Antisense modulation of CD40 expressionISIS PHARMACEUTICALS INC·Filed 2006·Granted Jun 29, 2010·189 cites·46 claims
- 0499US7683036B2Oligomeric compounds and compositions for use in modulation of small non-coding RNAsREGULUS THERAPEUTICS INC·Filed 2004·Granted Mar 23, 2010·182 cites·40 claims
- 0599US6426220B1Antisense modulation of calreticulin expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Jul 30, 2002·228 cites·26 claims
- 0699US6365354B1Antisense modulation of lysophospholipase I expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Apr 2, 2002·366 cites·26 claims
- 0798US8546350B2Oligomeric compounds and compositions for use in modulation of small non-coding RNAsBENNETT C FRANK·Filed 2012·Granted Oct 1, 2013·35 cites·22 claims
- 0898US8501703B2Chimeric oligomeric compounds for modulation of splicingBENNETT C FRANK·Filed 2006·Granted Aug 6, 2013·99 cites·24 claims
- 0998US8133876B2Oligomeric compounds and compositions for use in modulation of small non-coding RNAsBENNETT C FRANK·Filed 2008·Granted Mar 13, 2012·44 cites·17 claims
- 1098US7622455B2Methods for slowing familial ALS disease progressionISIS PHARMACEUTICALS INC·Filed 2006·Granted Nov 24, 2009·42 cites·20 claims
- 1198US7235653B2Oligonucleotide compositions and methods for the modulation of the expression of B7 proteinISIS PHARMACEUTICALS INC·Filed 2003·Granted Jun 26, 2007·117 cites·11 claims
- 1298US6710174B2Antisense inhibition of vascular endothelial growth factor receptor-1 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Mar 23, 2004·155 cites·1 claims
- 1398US6210892B1Alteration of cellular behavior by antisense modulation of mRNA processingISIS PHARMACEUTICALS INC·Filed 1999·Granted Apr 3, 2001·358 cites·31 claims
- 1498US5998148AAntisense modulation of microtubule-associated protein 4 expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Dec 7, 1999·514 cites·14 claims
- 1598US5801154AAntisense oligonucleotide modulation of multidrug resistance-associated proteinISIS PHARMACEUTICALS INC·Filed 1997·Granted Sep 1, 1998·1.6k cites·35 claims
- 1697US9717750B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2015·Granted Aug 1, 2017·26 cites·42 claims
- 1797US9057066B2Compositions and their uses directed to huntingtinISIS PHARMACEUTICALS INC·Filed 2012·Granted Jun 16, 2015·37 cites·17 claims
- 1897US8980853B2Compositions and methods for modulation of SMN2 splicing in a subjectBENNETT C FRANK·Filed 2010·Granted Mar 17, 2015·48 cites·4 claims
- 1997US8697663B2Oligomeric compounds and compositions for use in modulation of small non-coding RNAsBENNETT C FRANK·Filed 2008·Granted Apr 15, 2014·26 cites·28 claims
- 2097US8258109B2Compositions and methods for modulation of LMNA expressionBENNETT C FRANK·Filed 2006·Granted Sep 4, 2012·44 cites·17 claims
- 2197US7902163B2Antisense modulation of superoxide dismutase 1, soluble expressionISIS PHARMACEUTICALS INC·Filed 2006·Granted Mar 8, 2011·34 cites·17 claims
- 2297US7339051B2Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)ISIS PHARMACEUTICALS INC·Filed 2004·Granted Mar 4, 2008·158 cites·18 claims
- 2397US7148204B2Antisense modulation of bcl-x expressionISIS PHARMACEUTICALS INC·Filed 2002·Granted Dec 12, 2006·145 cites·16 claims
- 2496US11834660B2Compositions for modulating Ataxin 2 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·2 cites·23 claims
- 2596US10006027B2Methods for modulating Ataxin 2 expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Jun 26, 2018·21 cites·30 claims
- 2696US9765338B2Modulation of dystrophia myotonica-protein kinase (DMPK) expressionISIS PHARMACEUTICALS INC·Filed 2015·Granted Sep 19, 2017·67 cites·24 claims
- 2796US9157081B2Chimeric oligomeric compounds for modulation of splicingISIS PHARMACEUTICALS INC·Filed 2013·Granted Oct 13, 2015·29 cites·6 claims
- 2896US8957040B2Selective reduction of allelic variantsBENNETT C FRANK·Filed 2011·Granted Feb 17, 2015·42 cites·16 claims
- 2996US8637478B2Compounds and methods for modulating protein expressionBENNETT C FRANK·Filed 2008·Granted Jan 28, 2014·23 cites·17 claims
- 3096US8178506B2Oligomeric compounds and compositions for use in modulation of small non-coding RNAsLOLLO BRIDGET·Filed 2008·Granted May 15, 2012·37 cites·21 claims
- 3196US6656732B1Antisense inhibition of src-c expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Dec 2, 2003·63 cites·25 claims
- 3296US6172216B1Antisense modulation of BCL-X expressionISIS PHARMACEUTICALS INC·Filed 1998·Granted Jan 9, 2001·399 cites·35 claims
- 3396US6025198AAntisense modulation of Ship-2 expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Feb 15, 2000·107 cites·15 claims
- 3496US6001992AAntisense modulation of novel anti-apoptotic bcl-2-related proteinsISIS PHARMACEUTICALS INC·Filed 1999·Granted Dec 14, 1999·230 cites·40 claims
- 3596US5789573AAntisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2ISIS PHARMACEUTICALS INC·Filed 1996·Granted Aug 4, 1998·262 cites·4 claims
- 3695US9273315B2Modulation of huntingtin expressionISIS PHARMACEUTICALS INC·Filed 2014·Granted Mar 1, 2016·19 cites·14 claims
- 3795US9006198B2Selective reduction of allelic variantsBENNETT C FRANK·Filed 2011·Granted Apr 14, 2015·36 cites·20 claims
- 3895US7678895B2Antisense modulation of superoxide dismutase 1, soluble expressionISIS PHARMACEUTICALS INC·Filed 2006·Granted Mar 16, 2010·28 cites·34 claims
- 3995US7067497B2Modulation of telomere length by oligonucleotides having a G-core sequenceISIS PHARMACEUTICALS INC·Filed 2002·Granted Jun 27, 2006·57 cites·16 claims
- 4095US6335194B1Antisense modulation of survivin expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Jan 1, 2002·69 cites·23 claims
- 4195US5514788AOligonucleotide modulation of cell adhesionISIS PHARMACEUTICALS INC·Filed 1993·Granted May 7, 1996·171 cites·3 claims
- 4294US9926559B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2014·Granted Mar 27, 2018·12 cites·10 claims
- 4394US8946179B2Oligomeric compounds and compositions for use in modulation of small non-coding RNAsBENNETT C FRANK·Filed 2012·Granted Feb 3, 2015·12 cites·21 claims
- 4494US8211867B2Targeting microRNAs for the treatment of liver cancerBENNETT C FRANK·Filed 2008·Granted Jul 3, 2012·23 cites·27 claims
- 4594US7132530B2Antisense modulation of superoxide dismutase 1, soluble expressionISIS PHARMACEUTICALS INC·Filed 2003·Granted Nov 7, 2006·38 cites·22 claims
- 4693US10837016B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Nov 17, 2020·2 cites·16 claims
- 4793US9546368B2Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expressionIONIS PHARMACEUTICALS INC·Filed 2012·Granted Jan 17, 2017·16 cites·20 claims
- 4893US8859521B2Oligomeric compounds and compositions for use in modulation of small non-coding RNAsREGULUS THERAPEUTICS INC·Filed 2013·Granted Oct 14, 2014·7 cites·22 claims
- 4993US6265216B1Antisense modulation of cot oncogene expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Jul 24, 2001·29 cites·14 claims
- 5093US5985663AAntisense inhibition of interleukin-15 expressionISIS PHARMACEUTICALS INC·Filed 1998·Granted Nov 16, 1999·117 cites·19 claims
Showing the top 50 of 396 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when C. Frank Bennett files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →